Table 1.
Baseline characteristics of patients and tumors.
| Characteristics | All (n = 198) |
|---|---|
| Age (years, median [range]) | 67 (36–91) |
| Sex | |
| Male | 190 (96.0) |
| Female | 8 (4.0) |
| ECOG performance status | |
| 0–1 | 190 (96.0) |
| 2–3 | 8 (4.0) |
| BMI (kg/m2, median [range]) | 22.6 (15.1–33.3) |
| Hemoglobin (g/dL, median [range]) | 13.6 (8.2–17.6) |
| Albumin (g/dL, median [range]) | 4.2 (2.7–5.1) |
| Neutrophil / lymphocyte ratio | 2.3 (0.9–44.8) |
| Esophageal stent insertion | |
| No | 152 (76.8) |
| Yes | 46 (23.2) |
| Tumor location | |
| Cervical | 13 (6.6) |
| Upper thoracic | 42 (21.2) |
| Mid thoracic | 109 (55.1) |
| Lower thoracic | 34 (17.2) |
| Tumor histology | |
| Squamous cell carcinoma | 195 (98.5) |
| Adenocarcinoma | 3 (1.5) |
| Tumor differentiation | |
| Well differentiation | 25 (12.6) |
| Moderate differentiation | 113 (57.1) |
| Poorly differentiation | 41 (20.7) |
| Gx | 19 (9.6) |
| Clinical tumor stage | |
| T1 | 34 (17.2) |
| T2 | 31 (15.7) |
| T3 | 103 (52.0) |
| T4 | 30 (15.2) |
| Clinical nodal stage | |
| N0 | 51 (25.8) |
| N1 | 107 (54.0) |
| N2 | 22 (11.1) |
| N3 | 18 (9.1) |
| Chemotherapy regimen | |
| 5FU + Cisplatin | 191 (96.5) |
| Others | 7 (3.5) |
| Radiation dose (cGy, median [range]) | 6300 (3060–7020) |
| Consolidation chemotherapy | |
| No | 58 (29.3) |
| Yes | 140 (70.7) |
| CCRT complication* | |
| No | 132 (66.7) |
| Yes | 66 (33.3) |
ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; Gx, grade cannot be assessed; CCRT, concurrent chemo- and radiotherapy.
*
Esophagitis, general weakness, neutropenia, pneumonia, tracheo-esophageal fistula.